The research department at Alnylam is seeking a highly motivated postdoctoral research fellow with experience in statistical genetics, bioinformatics, computational biology or a related discipline and a passion for the application of human genetics to drug discovery and development. The successful candidate will be rigorously trained by our statistical genetics team and have the opportunity to drive specific research projects focused on mining of large genotype-phenotype datasets to make findings relevant to the discovery and development of new medicines. Alnylam is part of an effort to whole exome sequence all 500,000 participants from the UK biobank study. Projects aim to identify genetic contributions to liver and cardiometabolic diseases as well as broader efforts to understand the impact of rare loss-of-function variants and gene knockouts in humans. It is expected that the research conducted by the postdoctoral fellow will result in multiple high impact publications and contribute to the Alnylam pipeline.
The Alnylam Research post-doc program is designed to advance RNAi medicines through fresh perspectives and ideas from recent PhDs. Postdoc fellows will be provided the opportunity to collaborate with colleagues working in diverse disciplines including bioinformatics, RNAi lead discovery, RNAi biology, target discovery, and clinical development. They will be provided necessary budgetary support and infrastructure to execute the projects. In addition, postdocs are encouraged to participate at scientific conferences, collaborate with external partners as appropriate and publish high impact papers.
Summary of Key Goals • Discover new sequence variants associated with diseases of the liver and cardiometabolic diseases through analysis of a large genotype-phenotype dataset • Develop approaches to elucidate the consequences of naturally occurring knockouts of human genes across an array of phenotypic data including coded electronic medical records, blood biomarkers and MRI data • Contribute to the generation of publications, presentations and intellectual property • Maintain and organize computational pipelines, infrastructure and resources • Aid in the implementation of new statistical tools for large-scale genetic data analysis required to enable postdoctoral projects
• Recent PhD in statistical genetics, computational biology, bioinformatics or a related field • Expertise using the R programming language and Unix • Comfort using a variety of statistical methodologies to analyze biological data • Good working knowledge of human genetics • Experience working with large genotype-phenotype datasets is desirable
Alnylam’s Post Doctoral Program
• Postdoctoral fellowships are 2 years in length with the possibility to extend for a third year • Postdocs are encouraged to attend company meetings and will have broad exposure to RNAi drug discovery and development efforts within the company • Alnylam provides a scientifically rigorous environment and postdocs will have opportunities to present their work regularly within the company while also being supported to attend and speak at external conferences • Publication of work in high impact journals is expected after filling appropriate patents and internal reviews • Compensation and benefits are competitive with industry standards for post-doctoral programs. Alnylam Pharmaceuticals is an EEO employer committed to an exciting, diverse, and enriching work environment.
About Alnylam Pharmaceuticals
Alnylam was founded in 2002 on a revolutionary vision and bold mission which remain firmly in place today. We are leading the translation of RNA interference (RNAi) into a new class of innovative medicines with the potential to transform the lives of people with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system diseases with unmet need. Our first medicine, the first-ever RNAi therapeutic, has recently been approved by the FDA in the US for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults and by the European Medicines Agency in the EU for the treatment of hATTR amyloidosis in adults with stage 1 or stage 2 polyneuropathy. In addition, Alnylam has four investigational medicines in late-stage development. www.alnylam.com. Alnylam is proud to have been recognized as one of The Boston Globe’s Top Places to Work in 2015, 2016, 2017 and 2018- four years in a row!